Dogs to explain human retinal disease?

Article

A genetic mutation that is associated with recessive cone-rod dystrophy in dachshunds may play the same role in humans, according to a study in the August 2008 issue of Genome Research.

A genetic mutation that is associated with recessive cone-rod dystrophy in dachshunds may play the same role in humans, according to a study in the August 2008 issue of Genome Research.

Dr Frode Lingaas of the Department of Basic Sciences and Aquatic Medicine at the Norwegian School of Veterinary Science, Oslo, Norway, and colleagues performed genome-wide association-based Sibling Transmission Disequilibrium Test (sibTDT) analysis to identify and then resequence an area on canine chromosome 5, which contains more than 70 genes.

The analysis showed that, in dachshunds suffering from cone-rod dystrophy, one gene - nephronophthisis/nephroretinin 4 (NPHP4) - had an area missing, which produced a truncated protein that interferes with interaction in the eye but not the kidney (NPHP4's other biological target).

The team concluded that this mutation, the truncated protein produced by NPHP4, is responsible for the development of cone-rod dystrophy in a canine model. As other NPHP4 mutations have been associated with eye and kidney disease in humans, the team speculate that further investigation of this mutation could result in an explanation for similar degenerative retinal diseases in humans.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.